[HTML][HTML] Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations
D Koenig, S Savic Prince, SI Rothschild - Cancers, 2021 - mdpi.com
Simple Summary The treatment of advanced and metastatic non-small cell lung cancer
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
(NSCLC) has changed dramatically in recent years due to advanced molecular diagnostics …
[HTML][HTML] Targeted therapies in non-small cell lung cancer—beyond EGFR and ALK
SI Rothschild - Cancers, 2015 - mdpi.com
Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …
paradigm shift over the past decade. Advances in our understanding of the underlying …
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer (NSCLC)
N Barr Kumarakulasinghe, N Zanwijk, RA Soo - Respirology, 2015 - Wiley Online Library
Historically, patients with advanced stage non‐small cell lung cancer (NSCLC) were treated
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …
with chemotherapy alone, but a therapeutic plateau has been reached. Advances in the …
[HTML][HTML] Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
F Janku, DJ Stewart, R Kurzrock - Nature reviews Clinical oncology, 2010 - nature.com
Abstract Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC)
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
Targeted therapy for lung cancer: Beyond EGFR and ALK
M Herrera‐Juárez, C Serrano‐Gómez… - Cancer, 2023 - Wiley Online Library
Precision oncology comprises the set of strategies that aim to design the best cancer
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
treatment based on tumor biology. A recognized subset of patients with non‐small cell lung …
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application
P Maione, PC Sacco, A Sgambato… - … in medical oncology, 2015 - journals.sagepub.com
The discovery that a number of aberrant tumorigenic processes and signal transduction
pathways are mediated by druggable protein kinases has led to a revolutionary change in …
pathways are mediated by druggable protein kinases has led to a revolutionary change in …
Molecular therapeutic targets in non-small cell lung cancer
K Sankar, SM Gadgeel, A Qin - Expert review of anticancer therapy, 2020 - Taylor & Francis
Introduction Several targetable genetic alterations have been identified in non-small cell
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …
lung cancers (NSCLC) and drugs targeting these alterations have been approved for the …
[HTML][HTML] Advances in the development of molecularly targeted agents in non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
leading cause of cancer-related mortality. The traditional 'one-size-fits-all'treatment …
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities
Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …
[HTML][HTML] Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer
Advances in the treatment of non-small cell lung cancer (NSCLC) over the last decade have
predominantly involved the development of therapies directed at molecular targets such as …
predominantly involved the development of therapies directed at molecular targets such as …